BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31148369)

  • 1. In-Depth Proteomics Analysis to Identify Biomarkers of Papillary Thyroid Cancer Patients Older Than 45 Years with Different Degrees of Lymph Node Metastases.
    Zhan S; Wang T; Wang M; Li J; Ge W
    Proteomics Clin Appl; 2019 Sep; 13(5):e1900030. PubMed ID: 31148369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
    Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
    Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics study of serum exosomes from papillary thyroid cancer patients.
    Luo D; Zhan S; Xia W; Huang L; Ge W; Wang T
    Endocr Relat Cancer; 2018 Oct; 25(10):879-891. PubMed ID: 29895528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.
    Zhan S; Li J; Wang T; Ge W
    Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of tissue proteomics in patients with papillary thyroid microcarcinoma uncovers the underlying mechanism of lymph node metastasis and its significant sex disparities.
    Cao Z; Zhang Z; Tang X; Liu R; Wu M; Wu J; Liu Z
    Front Oncol; 2022; 12():887977. PubMed ID: 36106120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
    Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
    Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
    BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
    Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
    Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
    J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
    Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
    Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDLIM5 identified by label-free quantitative proteomics as a potential novel biomarker of papillary thyroid carcinoma.
    Wei X; Zhang Y; Yu S; Li S; Jiang W; Zhu Y; Xu Y; Yang C; Tian G; Mi J; Bergquist J; Zhao M; Song F
    Biochem Biophys Res Commun; 2018 May; 499(2):338-344. PubMed ID: 29574154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
    Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Toll-like Receptor 4 Overexpression in Papillary Thyroid Cancer by MAPK/ERK-Induced ETS1 Transcriptional Activity.
    Peyret V; Nazar M; Martín M; Quintar AA; Fernandez EA; Geysels RC; Fuziwara CS; Montesinos MM; Maldonado CA; Santisteban P; Kimura ET; Pellizas CG; Nicola JP; Masini-Repiso AM
    Mol Cancer Res; 2018 May; 16(5):833-845. PubMed ID: 29523762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.